Vaxart Inc

Vaxart insider trading, oral‑vaccine progress, FDA Fast Track and Phase‑3 plans revealed – see how clinical data and regulatory moves could shape investors’ future decisions.

Vaxart insider selling sparks questions about confidence, while the company’s oral flu vaccine platform and strategic pricing could still drive future growth.

CEO Lo Steven’s new Vaxart insider buys signal strong confidence in the oral vaccine platform, hinting at upcoming milestones that could lift the stock.